Astrana Health (ASTH) Set to Post Quarterly Earnings on Thursday

Astrana Health (NASDAQ:ASTH) is expected to be posting its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of $0.4573 per share and revenue of $1.02 billion for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 5:30 PM ET.

Astrana Health (NASDAQ:ASTH) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.46. The business had revenue of $972.52 million during the quarter, compared to analyst estimates of $985.62 million. Astrana Health had a return on equity of 10.30% and a net margin of 1.05%. The business’s revenue was up 48.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.19 earnings per share. On average, analysts expect Astrana Health to post $1.36 EPS for the current fiscal year and $1.93 EPS for the next fiscal year.

Astrana Health Price Performance

ASTH stock opened at $36.67 on Thursday. Astrana Health has a 1 year low of $18.08 and a 1 year high of $51.60. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.23 and a quick ratio of 1.23. The firm has a market capitalization of $2.04 billion, a PE ratio of 44.72 and a beta of 1.03. The business has a 50 day simple moving average of $37.19 and a 200-day simple moving average of $33.68.

Analyst Ratings Changes

A number of brokerages have issued reports on ASTH. BTIG Research raised their target price on Astrana Health from $50.00 to $65.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Barclays lifted their price target on Astrana Health from $50.00 to $53.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. TD Cowen boosted their price target on shares of Astrana Health from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. Truist Financial upped their price objective on shares of Astrana Health from $47.00 to $55.00 and gave the company a “buy” rating in a report on Monday, August 10th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Astrana Health in a report on Thursday, August 27th. Eight research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, Astrana Health has a consensus rating of “Moderate Buy” and an average price target of $49.88.

Astrana Health Company Profile

Astrana Health, Inc (NASDAQ: ASTH), formerly known as Apollo Medical Holdings, is a healthcare enablement company focused on helping providers and health plans deliver coordinated, value-based care. The company combines physician networks, care-management capabilities, technology and data analytics to support improved clinical outcomes and more efficient healthcare delivery.

Astrana Health’s services include population health management, physician practice support, utilization management, care coordination and clinical analytics.